Pathology experts to evaluate medical, surgical breast cancer treatment at World Senologyc Congress

Aug 31 2010

Spain will held the 16th World Senologyc Congress between the 20th and 22nd of October. This meeting will allow doctors to evaluate the progress achieved in medical and surgical breast cancer treatment and its future challenges. The best time to rebuilding breasts, how to preserve patients' fertility, the use of nodes self-transplant to treat lymphedema, the develop of new molecular targets and the use of stem cells will be some of the key issues to be treated during the congress.

Over 1.500 breast pathology experts will meet between the 20^th and 22^nd of October in the 16^th World Congress of the Senologic International Society (SIS). This meeting and the 29^th Congress of the Spanish Society of Senology and Breast Diseases (SESPM) will take place in the Valencia, coinciding with the International Breast Cancer Day.

According to Dr. Carlos Vázquez, president of the SIS and the SESPM, "this meeting will allow us to update the new advances in breast surgery, specially regarding to the sentinel node biopsy, and to study in depth the latest breast immediate rebuilding techniques and  radiotherapy standards". "We will also have the chance to asses with worldwide renowned experts about the radiology diagnosis methodology and its possible uses in life surgery", he adds.

From a socio-sanitary point of view, the congress' members will evaluate the efficacy of breast cancer screening using mammography and they will check the results obtain by the hospital breast units in terms of survival and quality of life. These structures allow patients to receive a complete and multidisciplinary management of their tumor.

On the other hand, according to Dr. Vicente Guillem, president of the Congress Scientific Committee, experts will also approach other interesting issues for patients' quality of life such as: the best time and best technique to undergo rebuilding surgery after a mastectomy; the chances for young patients to preserve the possibilities of getting pregnant in the future or the potential impact of pregnancy induction therapies. Other matters to study will be translational research in breast cancer -as lymphatic gland self-transplant to treat lymphedema, one of the most common consequences of surgery- the assessment of new molecular targets to develop more efficient and personalized treatments.

Many wellknown worldwide experts will attend to this Congress such as Prof. Veronessi, from Milan, Prof. Cezap, from Buenos Aires, Prof. Masia, from Barcelona, Prof. Muggia and Cordón-Cardo, both from New York, among others.